Severity of oxidative stress and inflammatory activation in end-stage heart failure patients are unaltered after 1month of left ventricular mechanical assistance

Cytokine

Volumn 59, Issue 1, 2012, Pages 138-144

  Caruso, Raffaele ^a   Verde, Alessandro ^a   Campolo, Jonica ^a   Milazzo, Filippo ^a   Russo, Claudio ^a   Boroni, Chiara ^a   Parolini, Marina ^a   Trunfio, Salvatore ^a   Paino, Roberto ^a   Martinelli, Luigi ^a   Frigerio, Maria ^a   Parodi, Oberdan ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Cytokines; ICU stay; LVAD; Oxidative stress; TSOFA score

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INOTROPIC AGENT; INTERLEUKIN 6; INTERLEUKIN 8; NEOPTERIN; PROSTAGLANDIN F2 ALPHA;

ADULT; ARTICLE; ASSISTED CIRCULATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; FEMALE; GRAFT RECIPIENT; HEART FAILURE; HEART HEMODYNAMICS; HOSPITALIZATION; HUMAN; INFLAMMATION; INTENSIVE CARE UNIT; LEFT VENTRICULAR ASSIST DEVICE; MALE; MULTIPLE ORGAN FAILURE; OXIDATIVE STRESS; PRIORITY JOURNAL; TOTAL SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE;

ADULT; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; HEART FAILURE; HEART-ASSIST DEVICES; HEMODYNAMICS; HOSPITALIZATION; HUMANS; INFLAMMATION; INTENSIVE CARE UNITS; INTERLEUKIN-6; ITALY; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROSTHESIS IMPLANTATION; TREATMENT OUTCOME;

EID: 84861662184     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.04.018     Document Type: Article

References (33)

1. Deng M.C., Edwards L.B., Hertz M.I., Rowe A.W., Keck B.M., Kormos R., et al. Mechanical circulatory support device database of the International Society for Heart and Lung Transplantation: Third Annual Report-2005. J Heart Lung Transplant 2005, 24:1182-1187.
2. Burkhoff D., Klotz S., Mancini D.M. LVAD-induced reverse remodeling: basic and clinical implications for myocardial recovery. J Card Fail 2006, 12:227-239.
3. Klotz S., Jan Danser A.H., Burkhoff D. Impact of left ventricular assist device (LVAD) support on the cardiac reverse remodeling process. Progr Bioph Mol Biol 2008, 97:479-496.
4. Chrysohoou C., Pitsavos C., Barbetseas J., Kotroyiannis I., Brili S., Vasiliadou K., et al. Chronic systemic inflammation accompanies impaired ventricular diastolic function, detected by Doppler imaging, in patients with newly diagnosed systolic heart failure (Hellenic Heart Failure Study). Heart Vessels 2009, 24:22-26.
5. Hofmann U., Heuer S., Meder K., Boehler J., Lange V., Quaschning T., et al. The proinflammatory cytokines TNF-alpha and IL-1 beta impair economy of contraction in human myocardium. Cytokine 2007, 39:157-162.
6. Hudzik B., Szkodzinski J., Romanowski W., Danikiewicz A., Wilczek K., Lekston A., et al. Serum interleukin-6 concentration reflects the extent of asymptomatic left ventricular dysfunction and predicts progression to heart failure in patients with stable coronary artery disease. Cytokine 2011, 54:266-271.
7. Opie L.H., Commerford P.J., Gersh B.J., Pfeffer M.A. Controversies in ventricular remodeling. Lancet 2006, 367:356-367.
8. El-Menyar A.A. Cytokines and myocardial dysfunction: state of the art. J Card Fail 2008, 14:61-74.
9. Matsumoto M., Tsujino T., Lee-Kawabata M., Naito Y., Sakoda T., Ohyanagi M., et al. Serum interleukin-6 and C-reactive protein are markedly elevated in acute decompensated heart failure patients with left ventricular systolic dysfunction. Cytokine 2010, 49:264-268.
10. Castro P.F., Greig D., Pérez O., Moraga F., Chiong M., Dìaz-Araya G., et al. Relation between oxidative stress, catecholamines, and impaired chronotropic response to exercise in patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Card 2003, 92:215-218.
11. Campolo J., Caruso R., De Maria R., Parolini M., Oliva F., Roubina E., et al. Aminothiol redox alterations in patients with chronic heart failure of ischaemic or non-ischaemic origin. J Cardiovasc Med 2007, 8:1024-1028.
12. Sawyer D.B., Siwik D., Xiao L., Pimentel D.R., Singh K., Colucci W.S. Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Card 2002, 34:379-388.
13. Vukasovica J.L., Di{dotless}́az-Arayab G., Turnerc E., Chiongb M., Uriartec P., Florenzanoa F., et al. Oxidative stress in pericardial fluid and plasma and its association with ventricular function. Int J Cardiol 2005, 101:197-201.
14. Mallat Z., Philip I., Lebret M., Chatel D., Maclouf J., Tedgui A. Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. Circulation 1998, 97:1536-1539.
15. Dang N.C., Topkara V.K., Mercando M., Kay J., Kruger K.H., Aboodi M.S., et al. Right heart failure after left ventricular assist device implantation in patients with chronic congestive heart failure. J Heart Lung Transplant 2006, 25:1-6.
16. Kavarana M.N., Pessin-Minsley M.S., Urtecho J., Catanese K.A., Flannery M., Oz M.C., et al. Right ventricular dysfunction and organ failure in left ventricular assist device recipients: a continuing problem. Ann Thoracic Surg 2002, 73:745-750.
17. Chen Y.S., Ko W.J., Lin F.Y., Huang S.C., Chou T.F., Chou N.K., et al. Preliminary result of an algorithm to select proper ventricular assist device for high-risk patients with extracorporeal membrane oxygenation support. J Heart Lung Transplant 2001, 20:850-857.
18. Palardy M., Nohria A., Rivero J., Lakdawala N., Campbell P., Kato M., et al. Right ventricular dysfunction during intensive pharmacologic unloading persists after mechanical unloading. J Card Fail 2010, 16:218-224.
19. Caruso R., Trunfio S., Milazzo F., Campolo J., De Maria R., Colombo T., et al. Early expression of pro- and anti-inflammatory cytokines in left ventricular assist device recipients with multiple organ failure syndrome. ASAIO J 2010, 56:313-318.
20. Caruso R., Garatti A., Sedda V., Milazzo F., Campolo J., Colombo T., et al. Pre-operative redox state affects 1-month survival in patients with advanced heart failure undergoing left ventricular assist device implantation. J Heart Lung Transplant 2007, 26:1177-1181.
21. Blum A. Heart failure - new insights. Isr Med Assoc J 2009, 11:105-111.
22. Birks E.J., Latif N., Owen V., Bowles C., Felkin L.E., Mullen A.J., et al. Quantitative myocardial cytokine expression and activation of the apoptotic pathway in patients who require left ventricular assist devices. Circulation 2001, 104:I-233-I-244.
23. Stevenson L.W., Pagani F.D., Young J.B., Jessup M., Miller L., Kormos R.L., et al. INTERMACS profiles of advanced heart failure: the current picture. J Heart Lung Transplant 2009, 28:535-541.
24. Lund L.H., Matthews J., Aaronson K. Patient selection for left ventricular assist device. Eur J Heart Fail 2010, 12:434-443.
25. HeartMateII Clinical Investigators Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. J Heart Lung Transplant 2010, 29:S1-39.
26. Tang D.G., Oyer P.E., Mallidi H.R. Ventricular assist devices: history, patient selection, and timing of therapy. J Cardiovasc Transl Res 2009, 2:159-167.
27. Masai T., Sawa Y., Ohtake S., Nishida T., Nishimura M., Fukushima N., et al. Hepatic dysfunction after left ventricular mechanical assist in patients with end-stage heart failure: role of inflammatory response and hepatic microcirculation. Ann Thorac Surg 2002, 73:549-555.
28. Ray K.K., Morrow D.A., Sabatine M.S., Shui A., Rifai N., Cannon C.P., et al. Long term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndromes. Circulation 2007, 115:3071-3078.
29. Brasier A.R. The nuclear factor-kB-interleukin-6 signalling pathway mediating vascular inflammation. Card Res 2010, 86:211-218.
30. Wei M., Kuukasjärvi P., Laurikka J., Kaukinen S., Honkonen E.L., Metsänoja R., et al. Relation of cytokines to vasodilation after coronary artery bypass grafting. World J Surg 2003, 27:1093-1098.
31. Cr Hampton., Verrier E.D. Systemic consequences of ventricular assist devices: alterations of coagulation, immune function, inflammation, and the neuroendocrine system. Artificial Organs 2002, 26:902-908.
32. Clark A.L., Loebe M., Potapov E.V., Egere K., Knosalla C., Hetzer R., et al. Ventricular assist device in severe heart failure. Effects on cytokines, complement and body weight. Eur Heart J 2001, 22:2275-2283.
33. Torre-Amione G., Stetson S.J., Youker K.A., Durand J.-B., Radovancevic B., Delgado R.M., et al. Decreased expression of tumor necrosis factor-a in failing human myocardium after mechanical circulatory support. A potential mechanism for cardiac recovery. Circulation 1999, 100:1189-1193.